BASKING RIDGE, N.J. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration ( FDA ) for an expanded label for gammaCore™ [non-invasive vagus
ROCKAWAY, N.J. , March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated March
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function post injury ROCKAWAY, N.J. , March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company,
gammaCore™ chosen by NHS England to be funded by the Innovation and Technology Payment Program (ITP) for the period of April 2019 to April 2020 to support adoption in the U.K. LONDON and BASKING RIDGE, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices ROCKAWAY, N.J. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and
BASKING RIDGE, N.J. , April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the
ROCKAWAY, NJ , April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2021 after the close of the market on Thursday, May 6, 2021 .
ROCKAWAY, N.J. , April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022 , after the close of the market on Thursday, May 5, 2022 .
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of